Cost-utility study of recombinant factor VIII in the treatment of hemophilia a in Mexico

被引：0
|
作者：
Soria-Cedillo, I. F. [1 ]
De la Mora-Chavez, T. [2 ]
Del Campo-Perez, M. [2 ]
Brugada-Cruces, C. [2 ]
Garcia-Contreras, F. [2 ]
机构：
[1] Univ Autonoma Estado Morelos, Cuernavaca, Morelos, Mexico
[2] Inst Mexicano Seguro Social, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70513-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A162 / A162
页数：1
相关论文
共 50 条
  • [1] Cost-utility study of recombinant factor VIII in the treatment of hemophilia A in Mexico
    Garcia-Contreras, F.
    De La Mora-Chavez, T.
    Del Campo-Perez, M.
    Brugada-Cruces, C.
    Soria-Cedillo, I.
    [J]. HAEMOPHILIA, 2008, 14 : 134 - 134
  • [2] Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden
    Henry, Nathaniel
    Joyanovic, Jelena
    Schlueter, Max
    Kritikou, Persefoni
    Wilson, Koo
    Myren, Karl-Johan
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (04) : 318 - 325
  • [3] Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A
    Farhad Lotfi
    Hamid Talebianpour
    Khosro Keshavarz
    Fatemeh Emadi
    Mohammad Reza Bordbar
    Peivand Bastani
    [J]. DARU Journal of Pharmaceutical Sciences, 2020, 28 : 287 - 293
  • [4] Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A
    Lotfi, Farhad
    Talebianpour, Hamid
    Keshavarz, Khosro
    Emadi, Fatemeh
    Bordbar, Mohammad Reza
    Bastani, Peivand
    [J]. DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 28 (01) : 287 - 293
  • [5] COST UTILITY ANALYSIS OF THE PROFILAXIS VERSUS ON-DEMAND TREATMENT WITH RECOMBINANT FACTOR IX FOR THE TREATMENT OF HEMOPHILIA B IN MEXICO
    Mucino-Ortega, E.
    Leyva-Bravo, V
    Gutierrez, C.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A103 - A104
  • [6] COST EFFECTIVENESS STUDY OF THE RECOMBINANT COAGULATION FACTOR VIII UNITED TO PROTEIN FC FOR THE TREATMENT OF HEMOPHILIA A IN CHILE
    Vargas, C.
    Balmaceda, C.
    Rodriguez, F.
    Rojas, R.
    Espinoza, M. A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A894 - A895
  • [7] Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis
    Grosse, Scott D.
    Chaugule, Shraddha S.
    Hay, Joel W.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (02) : 267 - 283
  • [8] Acquired hemophilia a hemostatic treatment with recombinant porcine factor VIII
    Sobolewska, A.
    Urbanska, A.
    Bednarska, M.
    Zawadzka, I.
    Witkowski, M.
    [J]. CLINICA CHIMICA ACTA, 2024, 558
  • [9] Recombinant factor VIII: past, present and future of treatment of hemophilia A
    Raso, S.
    Hermans, C.
    [J]. DRUGS OF TODAY, 2018, 54 (04) : 269 - 281
  • [10] Treatment and Prophylaxis of Hemophilia A Progress with Improved Recombinant Factor VIII
    Gruetzner, Karen
    [J]. THROMBOSIS AND HAEMOSTASIS, 2016, 116 (03) : 191 - 192
12345